

SAFETY DATA SHEET

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation

MAb Anti-Human TF IgG, 0.5 mg

of the mixture

Registration number

Synonyms None. **Product code** 4509

01-December-2017 Issue date

02 Version number

26-July-2017 **Revision date** Supersedes date 11-June-2015

1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses Research use only.

Uses advised against Use in accordance with supplier's recommendations.

1.3. Details of the supplier of the safety data sheet

Corporate Headquarters BioMedica Diagnostics Inc.

94 Wentworth Road, PO Box 1030

Windsor, Nova Scotia CANADA B0N 2T0

Corporate Phone: 1-902-798-5105 Contact person

Corporate Fax: 1-902-798-1025 Email: info@biomedicadiagnostics.com Website: www.biomedicadiagnostics.com

1.4. Emergency telephone

number

US, Canada, Puerto Rico & Virgin Islands 1-800-255-3924

International +1-813-248-0585 Australia 1-300-954-583

Brazil 0-800-591-6042 China 400-120-0751 India 000-800-100-4086 Mexico 01-800-099-0731

Contract number MIS9591327

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

The mixture has been assessed and/or tested for its physical, health and environmental hazards and the following classification

Classification according to Regulation (EC) No 1272/2008 as amended

This mixture does not meet the criteria for classification according to Regulation (EC) 1272/2008 as amended.

Hazard summary Avoid contact with eyes and skin. Do not ingest or inhale.

2.2. Label elements

Label according to Regulation (EC) No. 1272/2008 as amended

None. **Hazard pictograms** Signal word None.

The mixture does not meet the criteria for classification. **Hazard statements**

Precautionary statements

MAb Anti-Human TF IgG, 0.5 mg

Prevention Observe good laboratory hygiene practices.

Response Wash with plenty of water.

Store away from incompatible materials. Storage

Disposal Dispose of waste and residues in accordance with local authority requirements.

Supplemental label information

2.3. Other hazards Not a PBT or vPvB substance or mixture.

926517 Version #: 02 Revision date: 26-July-2017 Issue date: 01-December-2017

SDS UK

SECTION 3: Composition/information on ingredients

3.2. Mixtures

General information

Chemical name	%	CAS-No. / EC No.	REACH Registration No.	INDEX No.	Notes
Sodium chloride	20 -< 30	7647-14-5 231-598-3	01-2119485491-33-XXXX	-	
Classification: -					
Sodium phosphate dibasic anhydrous	3 - < 5	7558-79-4 231-448-7	-	-	
Classification: Eye Irrit. 2;1	1 319				

Composition comments

All concentrations are in percent by weight unless ingredient is a gas. Gas concentrations are in

percent by volume.

SECTION 4: First aid measures

General information Ensure that medical personnel are aware of the material(s) involved, and take precautions to

4.1. Description of first aid measures

Inhalation Move to fresh air. If breathing is difficult, give oxygen. Get medical attention if any discomfort

continues.

Skin contact For skin contact flush with large amounts of water while removing contaminated clothing. Get

medical attention if irritation develops and persists.

Eye contact In case of contact, immediately flush eyes with fresh water for at least 15 minutes while holding the

eyelids open. Remove contact lenses if worn. Get medical attention if irritation persists.

Ingestion Rinse mouth thoroughly if dust is ingested. Get medical advice/attention if you feel unwell.

4.2. Most important symptoms and effects, both acute and

delaved

Dust may cause eye, skin and respiratory tract irritation.

4.3. Indication of any immediate medical attention and special treatment needed Provide general supportive measures and treat symptomatically.

SECTION 5: Firefighting measures

General fire hazards No unusual fire or explosion hazards noted.

5.1. Extinguishing media

Suitable extinguishing

Water spray, carbon dioxide, dry chemical or alcohol-resistant foam.

Unsuitable extinguishing

media

media

None known.

5.2. Special hazards arising from the substance or mixture Hydrogen chloride gas. Sodium oxides.

5.3. Advice for firefighters

Special protective equipment for firefighters

Selection of respiratory protection for firefighting: follow the general fire precautions indicated in the workplace. Self-contained breathing apparatus and full protective clothing must be worn in

case of fire.

Special fire fighting

procedures

Use standard firefighting procedures and consider the hazards of other involved materials.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency

No special precautions are necessary beyond normal good hygiene practices. See Section 8 of the

personnel SDS for additional personal protection advice when handling this product.

For emergency responders Use personal protection recommended in Section 8 of the SDS. Avoid discharge into drains, water courses or onto the ground.

6.2. Environmental precautions

6.3. Methods and material for containment and cleaning up Avoid dust formation. Sweep or scoop up and remove.

6.4. Reference to other

sections

For personal protection, see Section 8 of the SDS. For waste disposal, see Section 13 of the SDS.

MAb Anti-Human TF IgG, 0.5 mg 926517 Version #: 02 Revision date: 26-July-2017 Issue date: 01-December-2017

SECTION 7: Handling and storage

7.1. Precautions for safe

handling

Avoid prolonged exposure. Avoid contact with skin and eyes.

7.2. Conditions for safe storage, including any incompatibilities

Store in a cool, dry, well-ventilated place. Store in a closed container away from incompatible

materials.

7.3. Specific end use(s) Research use only.

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

No exposure limits noted for ingredient(s). Occupational exposure limits

No biological exposure limits noted for the ingredient(s). **Biological limit values**

Recommended monitoring

procedures

Follow standard monitoring procedures.

Derived no-effect level (DNEL) Not available. Not available.

Predicted no effect concentrations (PNECs)

8.2. Exposure controls

Appropriate engineering No special ventilation requirements.

controls

Individual protection measures, such as personal protective equipment

General information Personal protective equipment should be chosen according to the CEN standards and in

discussion with the supplier of the personal protective equipment.

Wear dust-resistant safety goggles. Eye/face protection

Skin protection

- Hand protection It is a good industrial hygiene practice to minimise skin contact. Chemical resistant gloves are

- Other It is a good industrial hygiene practice to minimise skin contact.

In case of inadequate ventilation or risk of inhalation of dust, use suitable respiratory equipment Respiratory protection

with particle filter.

Thermal hazards Wear appropriate thermal protective clothing, when necessary.

Handle in accordance with good industrial hygiene and safety practices. Hygiene measures

Environmental exposure

controls

Inform appropriate managerial or supervisory personnel of all environmental releases.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

White powder. **Appearance**

Physical state Solid. **Form** Powder Not available. Colour Not available. Odour Not available. **Odour threshold**

6.8

Melting point/freezing point Not available. Initial boiling point and boiling Not available.

range

Not available. Flash point Not available. **Evaporation rate** Not available Flammability (solid, gas)

Upper/lower flammability or explosive limits

Flammability limit - lower (%)

Not available. Flammability limit - upper

(%)

Not available. Vapour pressure Vapour density Not available.

MAb Anti-Human TF IgG, 0.5 mg

926517 Version #: 02 Revision date: 26-July-2017 Issue date: 01-December-2017

Not available.

Not available. Relative density Water soluble. Solubility(ies) Not available. **Partition coefficient**

(n-octanol/water)

Not available. **Auto-ignition temperature** Not available. **Decomposition temperature** Not available. **Viscosity** Not available. **Explosive properties** Not available. **Oxidizing properties**

No relevant additional information available. 9.2. Other information

SECTION 10: Stability and reactivity

10.1. Reactivity Stable at normal conditions.

Material is stable under normal conditions. 10.2. Chemical stability

10.3. Possibility of hazardous

reactions

No data available.

10.4. Conditions to avoid Keep away from heat.

10.5. Incompatible materials Strong oxidising agents. Strong acids.

10.6. Hazardous Carbon oxides.

decomposition products

SECTION 11: Toxicological information

Information on likely routes of exposure

Inhalation Dust may irritate respiratory system.

Skin contact Dust may irritate skin.

Eye contact Dust in the eyes will cause irritation. May cause discomfort if swallowed. Ingestion

Mechanical irritation of skin, eyes and respiratory system. **Symptoms**

11.1. Information on toxicological effects

May cause discomfort if swallowed. **Acute toxicity**

Components **Species Test results**

Sodium chloride (CAS 7647-14-5)

Acute

Dermal

LD50 Rabbit > 10000 mg/kg

Oral

LD50 Rat > 3980 mg/kg

Other

Respiratory sensitisation

LD50 Mouse 2602 mg/kg

Skin corrosion/irritation Dust may irritate skin.

irritation

Serious eye damage/eye Dust may irritate the eyes.

Not classified. Skin sensitisation Germ cell mutagenicity Not classified. Not classified. Carcinogenicity Not classified. Reproductive toxicity

Specific target organ toxicity -

single exposure

Not classified.

Not classified.

Specific target organ toxicity -

repeated exposure

Not classified.

Not classified. Aspiration hazard

Mixture versus substance

information

Not available.

MAb Anti-Human TF IgG, 0.5 mg 926517 Version #: 02 Revision date: 26-July-2017 Issue date: 01-December-2017 Other information Not available.

SECTION 12: Ecological information

12.1. Toxicity

Components Species Test results

Sodium chloride (CAS 7647-14-5)

Aquatic

Crustacea EC50 Water flea (Daphnia magna) 874 mg/l, 48 hours

12.2. Persistence and

degradability

No data available.

12.3. Bioaccumulative potential

No data available.
Not available.

n-octanol/water (log Kow)

Bioconcentration factor (BCF) Not available.

12.4. Mobility in soil Not available.

Mobility in general The product is soluble in water.

12.5. Results of PBT

Partition coefficient

and vPvB assessment

Not a PBT or vPvB substance or mixture.

12.6. Other adverse effects No data available.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Residual waste Dispose in accordance with all applicable regulations.

Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal.

EU waste codeThe Waste code should be assigned in discussion between the user, the producer and the waste

disposal company.

Disposal methods/information Collect and reclaim or dispose in sealed containers at licensed waste disposal site. Contaminated

instruments and surfaces should be disinfected in accordance with your employer's

chemical-specific and universal/standard precautions.

SECTION 14: Transport information

ADR

Not regulated as dangerous goods.

RID

Not regulated as dangerous goods.

ADN

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

14.7. Transport in bulk according to Annex II of

Not applicable.

MARPOL 73/78 and the IBC

Code

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

EU regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I and II, as amended

Not listed

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended

Not listed.

 $Regulation \ (EC) \ No. \ 689/2008 \ concerning \ the \ export \ and \ import \ of \ dangerous \ chemicals, \ Annex \ I, \ part \ 1 \ as \ amended$

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended

Not listed.

MAb Anti-Human TF IgG, 0.5 mg $\,$

SDS UK

926517 Version #: 02 Revision date: 26-July-2017 Issue date: 01-December-2017

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended

Not listed

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry, as amended

Not listed.

Regulation (EC) No. 1907/2006, REACH Article 59(10) Candidate List as currently published by ECHA

Not listed.

Authorisations

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended

Not listed.

Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work, as amended

Not listed.

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding, as amended

Not listed

Other EU regulations

Directive 2012/18/EU on major accident hazards involving dangerous substances

Not listed.

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Not listed

Directive 94/33/EC on the protection of young people at work

Not listed.

Other regulations This product does not meet the criteria for classification according to Regulation (EC) 1272/2008

(CLP Regulation) and Directive 67/548/EEC and their amendments respectively. This Safety Data

Sheet complies with the requirements of Regulation (EC) No 1907/2006 as amended.

National regulations

15.2. Chemical safety

assessment

Follow national regulation for work with chemical agents. No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

List of abbreviations

DNEL: Derived No-Effect Level.

PNEC: Predicted No-Effect Concentration.

Not available. References

Information on evaluation method leading to the classification of mixture

The classification for health and environmental hazards is derived by a combination of calculation

methods and test data, if available.

Full text of any H-statements not written out in full under

Sections 2 to 15

H319 Causes serious eye irritation.

Training information

Follow training instructions when handling this material.

Disclaimer

The information above is provided in good faith. It is believed to be accurate and represents the best information currently available to us. HOWEVER, WE MAKE NO WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR OF ANY OTHER TYPE, EXPRESSED OR IMPLIED, WITH RESPECT TO PRODUCTS DESCRIBED OR DATA OR INFORMATION PROVIDED, AND WE ASSUME NO LIABILITY RESULTING FROM THE USE OF SUCH PRODUCTS, DATA OR INFORMATION. Users should make their own investigations to determine the suitability of the information for their particular purposes, and the user assumes all risk arising from their use of the material. The user is required to comply with all laws and regulations relating to the purchase, use, storage and disposal of the material, and must be familiar with and follow generally accepted safe handling procedures. In no event shall BioMedica

Diagnostics be liable for any claims, losses, or damages of any individual or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if

BioMedica Diagnostics has been advised of the possibility of such damages.

SDS UK